Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
100.49
+6.69 (7.13%)
At close: Dec 5, 2025, 4:00 PM EST
102.49
+2.00 (1.99%)
After-hours: Dec 5, 2025, 5:49 PM EST
Palvella Therapeutics Employees
Palvella Therapeutics had 14 employees as of December 31, 2024.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,312,143
Market Cap
1.19B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PVLA News
- 24 days ago - Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies - GlobeNewsWire
- 4 weeks ago - Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025 - GlobeNewsWire
- 7 weeks ago - U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations - GlobeNewsWire
- 2 months ago - Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies - GlobeNewsWire
- 2 months ago - Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM - Seeking Alpha
- 2 months ago - Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy - GlobeNewsWire